Clinical applications of fibroblast activation proteintargeted theranostics in oncologic and nononcologic disease:Current status and future directions  

作　　者：Hao Fu Wei Guo Jingxiong Huang Hua Wu Haojun Chen 

机构地区：[1]Department of Nuclear Medicine and Minnan PET Center,Xiamen Key Laboratory of Radiopharmaceuticals,The First Affiliated Hospital of Xiamen University,School of Medicine,Xiamen University,Xiamen,Fujian,China

出　　处：《iRADIOLOGY》2023年第4期340-361,共22页融合影像学(英文)

基　　金：Key Scientific Research Program for Young Scholars in Fujian,Grant/Award Number:2021ZQNZD016;Fujian Natural Science Foundation for Distinguished Young Scholars,Grant/Award Number:2022D005;Medical and Health Guidance Projects of Xiamen,Grant/Award Numbers:3502Z20209269,3502Z20224ZD1001;National Natural Science Foundation of China,Grant/Award Numbers:82071961,82102094;Fujian Natural Science Foundation for Youth Innovation,Grant/Award Number:2022J05314;Fujian Research and Training Grants for Young and Middle-Aged Leaders in Healthcare。

摘　　要：Quinoline-based fibroblast activation protein(FAP)inhibitor(FAPI)-based positron emission tomography(PET)imaging and radioligand therapy(RLT)are being investigated for use in a wide variety of diseases,and recent results have been promising.This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with ^(18)F-fluorodeoxyglucose.In addition,we summarize the previously published FAP-targeted RLT data and discuss its current clinical use and future potential.Our qualitative summary can inform future research directions,medical guidelines,and optimal clinical decision-making.

关 键 词：FAPI-PET FAP-targeted radioligand therapy FAP-targeted theranostics fibroblast activation protein RADIOPHARMACEUTICALS 

分 类 号：R73[医药卫生—肿瘤]